An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Reads0
Chats0
TLDR
The standard of care (SOC) therapy for patients with chronic hepatitis C virus (HCV) infection has been the use of both peginterferon (PegIFN) and ribavirin (RBV) as mentioned in this paper.About:
This article is published in Hepatology.The article was published on 2011-10-01 and is currently open access. It has received 1117 citations till now. The article focuses on the topics: Boceprevir & Telaprevir.read more
Citations
More filters
Journal ArticleDOI
Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C
Pamela S. Belperio,Elizabeth W. Hwang,Elizabeth W. Hwang,I. Chun Thomas,Larry A. Mole,Ramsey Cheung,Ramsey Cheung,Lisa I. Backus +7 more
TL;DR: HCV-infected veterans treated in routine medical practice with DAA-based regimens (BOC or TVR) had rates of early response comparable with those reported in clinical trials, however, they had higher rates of futility and early discontinuation than clinical trial participants.
Journal ArticleDOI
Management of the transplant recipient with chronic hepatitis C.
TL;DR: Rapid advances in new drug therapy for HCV promise to improve outcomes, reduce side effects and drug-drug interaction, shorten treatment duration, and simplify treatment regimens.
Journal ArticleDOI
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye
TL;DR: The first-generation protease inhibitors of hepatitis C virus, telaprevir and boceprevir, are the harbingers of important advances in the treatment of chronic HCV infection and response rates in patients with cirrhosis are improved compared with PEG-IFN and RBV treatment, they remain suboptimal.
Journal ArticleDOI
The changing face of hepatitis C in the new era of direct-acting antivirals
Vincent Soriano,Pablo Labarga,José Vicente Fernández-Montero,José Miguel Benito,Eva Poveda,Norma Rallón,Clara Sánchez,Eugenia Vispo,Pablo Barreiro +8 more
TL;DR: The future will probably see a progressive marginalization of residual HCV populations, with increasing over-representation of illegal immigrants, alcohol abusers, intravenous drug users and the mentally disabled.
Journal ArticleDOI
Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection
Malte H. Wehmeyer,Friederike Eißing,Sabine Jordan,C Röder,Annette Hennigs,Olaf Degen,Anja Hüfner,Sandra Hertling,Stefan Schmiedel,Martina Sterneck,Jan van Lunzen,Ansgar W. Lohse,Julian Schulze zur Wiesch,Stefan Lüth +13 more
TL;DR: The frequency of SVR in a “real-life” treatment setting is slightly lower as compared to the results of the phase III trials for telaprevir or boceprevir, especially in patients with liver cirrhosis.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Dongliang Ge,Jacques Fellay,Alexander J. Thompson,Jason Simon,Kevin V. Shianna,Thomas J. Urban,Erin L. Heinzen,Ping Qiu,Arthur H. Bertelsen,Andrew J. Muir,Mark S. Sulkowski,John G. McHutchison,David Goldstein +12 more
TL;DR: It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more
TL;DR: Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
Related Papers (5)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more